The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy
Open accessAbstract
Objective: To study disease severity and response to therapy in a large cohort of patients with anti-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)-associated myositis. Methods: Muscle strength, creatine kinase levels and treatments were assessed in anti-HMGCR-positive patients at each clinical visit. Univariate and multivariate analyses were used to analyse the influence of clinical characteristics on strength and the change in strength over time. Whole exome sequencing was performed in a subset of patients. Results: . Among 50 patients followed for ⩾2 years, only 22 (44%) reached full strength with immunosuppressive therapy; even among those with full strength, 55% continued to have CK levels in excess of 500 IU/l and only three could be tapered off immunosuppressive therapy. Both univariate and multivariate analysis showed that patients who were older at disease onset were stronger at all time points (P < 0.001) and improved faster (P < 0.008) than younger patients; a history of statin exposure was not independently associated with the improvement rate. Younger patients were more likely to have refractory disease (P = 0.02) than older patients. Among eight refractory patients with DNA available for testing, whole exome sequencing did not reveal pathogenic mutations in known dystrophy genes. The risk of cancer was not increased in anti-HMGCR myositis patients compared with the general population. Conclusions: Anti-HMGCR myositis is usually a chronic disease requiring long-term immunosuppression. Although younger patients had more severe disease and a worse prognosis than older patients, they did not have evidence of a known co-existing muscular dystrophy to explain their persistent, and sometimes progressive, muscle weakness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statin-Associated Autoimmune Myopathy
Mammen, A. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515161 · Cited by 366
Self-citation
Cited by
224th ENMC International Workshop:
Allenbach, Y., Mammen, A. L., Benveniste, O., Stenzel, W., Allenbach, Y., Amato, A., Aussey, A., Benveniste, O., De Bleecker, J., de Groot, I., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.09.016 · Cited by 582
Self-citationClassification and management of adult inflammatory myopathies
Selva-O'Callaghan, A., Pinal-Fernandez, I., Trallero-Araguás, E., Milisenda, J. C., Grau-Junyent, J. M., & Mammen, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30254-0 · Cited by 430
Self-citationMcHugh, N. J., & Tansley, S. L. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.56 · Cited by 390
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
Allenbach, Y., Benveniste, O., Stenzel, W., & Boyer, O. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00515-9 · Cited by 335
Immune-Mediated Necrotizing Myopathy
Pinal-Fernandez, I., Casal-Dominguez, M., & Mammen, A. L. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0732-6 · Cited by 297
Self-citation
Metadata
- Authors
- Tiniakou, E., Pinal-Fernandez, I., Lloyd, T. E., Albayda, J., Paik, J., Werner, J. L., Parks, C. A., Casciola-Rosen, L., Christopher-Stine, L., & Mammen, A. L.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-01-17
- Volume
- 56
- Issue
- 5
- Pages
- kew470
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2574831313
- Cited by
- 183
- References
- 1
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. https://app.cochat.ai/papers/10.1093/rheumatology/kew470
- The paper
- Tiniakou, E., Pinal-Fernandez, I., Lloyd, T. E., Albayda, J., Paik, J., Werner, J. L., Parks, C. A., Casciola-Rosen, L., Christopher-Stine, L., & Mammen, A. L. (2017). More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology. https://doi.org/10.1093/rheumatology/kew470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.